A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
Phase of Trial: Phase III
Latest Information Update: 08 Jul 2019
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Male osteoporosis; Osteoporosis
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 04 Mar 2019 Status changed from active, no longer recruiting to completed.
- 22 Feb 2019 Planned End Date changed from 15 Apr 2019 to 27 Feb 2019.
- 22 Feb 2019 Planned primary completion date changed from 15 Apr 2019 to 27 Feb 2019.